5881-57-2 Usage
Molecular Structure
The compound has a pyrrole ring, a carboxylic acid group, a nitrophenyl group, and an ethyl ester group.
Molecular Weight
278.28 g/mol
Appearance
The compound is a pale yellow solid.
Solubility
It is soluble in common organic solvents such as ethanol, methanol, and dichloromethane.
Reactivity
The compound can undergo various chemical reactions due to the presence of the pyrrole ring, carboxylic acid, and nitrophenyl group.
Synthesis
The compound can be synthesized through various methods, including the condensation of the corresponding aldehyde with an amino acid.
Industrial Applications
The compound has potential uses in the synthesis of various organic compounds, pharmaceuticals, drug delivery systems, and as a building block for the production of new drugs.
Research Applications
The compound can be used as a precursor for the synthesis of dyes and pigments, and in the study of chemical reactions involving the pyrrole ring, carboxylic acid, and nitrophenyl group.
Check Digit Verification of cas no
The CAS Registry Mumber 5881-57-2 includes 7 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 4 digits, 5,8,8 and 1 respectively; the second part has 2 digits, 5 and 7 respectively.
Calculate Digit Verification of CAS Registry Number 5881-57:
(6*5)+(5*8)+(4*8)+(3*1)+(2*5)+(1*7)=122
122 % 10 = 2
So 5881-57-2 is a valid CAS Registry Number.
5881-57-2Relevant academic research and scientific papers
Virtual screening and further development of novel ALK inhibitors
Okamoto, Masako,Kojima, Hirotatsu,Saito, Nae,Okabe, Takayoshi,Masuda, Yoshiaki,Furuya, Toshio,Nagano, Tetsuo
experimental part, p. 3086 - 3095 (2011/06/26)
Anaplastic lymphoma kinase (ALK) has been in the spotlight in recent years as a promising new target for therapy of non-small-cell lung cancer (NSCLC). Since the identification of the echinoderm microtubule-associated protein-like 4 (EML4)-ALK fusion gene in some NSCLC patients was reported in 2007, various research groups have been seeking ALK inhibitors. Above all, crizotinib (PF-02341066) has been under clinical trial, and its therapeutic efficacy of inhibiting ALK in NSCLC has been reported. Among anticancer drugs, drug resistance appears frequently necessitating various kinds of inhibitors. We identified novel ALK inhibitors by virtual screening from the public chemical library collected by the Chemical Biology Research Initiative (CBRI) at the University of Tokyo, and inhibitors that are more potent were developed.
